-
公开(公告)号：US5911165A
公开(公告)日：1999-06-08
申请号：US864797
申请日：1997-05-29
Applicant: John W. Guo , Rajiv Nayar
Inventor： John W. Guo , Rajiv Nayar
CPC classification number: G01N3/24 , G01N2203/0017 , G01N2203/0025 , G01N2203/0089 , G01N33/4905
Abstract: An improved method and device for measuring the mechanical properties of fibrin clots. A mixture of fibrinogen and thrombin is formed between two synthetic polymeric substrate materials and allowed to form a fibrin clot. The force required to separate the substrate materials is then measured and indicates the strength of the clot.
Abstract translation: 一种用于测量纤维蛋白凝块的机械性能的改进方法和装置。 在两种合成的聚合物底物材料之间形成纤维蛋白原和凝血酶的混合物，并使其形成纤维蛋白凝块。 然后测量分离底物材料所需的力，并指示凝块的强度。
-
2.发明授权Stabilized albumin-free recombinant factor VII preparation having a low sugar content 失效具有低糖含量的稳定化的无白蛋白的重组因子VIII制剂
公开(公告)号：US5874408A
公开(公告)日：1999-02-23
申请号：US86776
申请日：1998-05-28
Applicant: Rajiv Nayar
Inventor： Rajiv Nayar
IPC: A61K38/43 , A61K9/19 , A61K38/37 , A61K47/00 , A61K47/02 , A61K47/18 , A61K47/26 , C07K14/755 , A61K35/16 , A61K38/00 , A61K38/16
CPC classification number: A61K38/37 , A61K9/19 , A61K47/02 , A61K47/183 , A61K47/26
Abstract: A stable albumin-free Recombinant Factor VIII (rFVIII) formulation in lyophilized form having both crystalline and amorphous components and comprising, when reconstituted with water, about 65 to 400 mM glycine, up to 50 mM histidine, 15 to 60 mM sucrose, up to 50 mM NaCl (up to 100 mM NaCl if cake appearance not critical), up to 5 mM CaCl.sub.2 and 50 to 1500 lU/ml of rFVIII. A very preferred formulation comprises upon reconstitution with water about 290 mM glycine, 20 mM histidine, 30 mM sucrose, 30 mM NaCl, 2.5 mM CaCl.sub.2 and 50 to 1500 lU/ml of rFVIII. The residual water content of the lyophilized preparation is about 1 to 3% by weight, preferably about 1% by weight.
Abstract translation: 一种稳定的无白蛋白的重组因子VIII（rFVIII）制剂，其冻干形式具有结晶和无定形组分，并且当与水重构时，包含约65至400mM甘氨酸，高达50mM组氨酸，15至60mM蔗糖， 50mM NaCl（如果蛋糕外观不严格，高达100mM NaCl），高达5mM CaCl 2和50至1500U / ml的rFVIII。 非常优选的制剂包括与水重构约290mM甘氨酸，20mM组氨酸，30mM蔗糖，30mM NaCl，2.5mM CaCl 2和50至1500U / ml的rFVIII。 冻干制剂的残留水含量为约1至3重量％，优选约1重量％。
-
公开(公告)号：US4916118A
公开(公告)日：1990-04-10
申请号：US84636
申请日：1987-08-12
Applicant: Isaiah J. Fidler , Kiyoshi Morikawa , Rajiv Nayar
Inventor： Isaiah J. Fidler , Kiyoshi Morikawa , Rajiv Nayar
Abstract: The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate chemotactic peptides such as N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes stimulate macrophage activity which is especially useful in the cancer therapy for combating metastatic tumor cells and for treatment of chronic infections.
Abstract translation: 本发明涉及包含磷脂酰丝氨酸和磷脂酰胆碱或脂质体形式的磷脂酰乙醇胺衍生物的药物给药系统，其包封趋化肽如N-甲酰基-L-甲硫氨酰-L-亮氨酰-L-苯丙氨酸。 脂质体通过常规分散方法制备。 当以脂质体形式施用时，药物施用系统刺激巨噬细胞活性，其特别可用于抗癌转移肿瘤细胞和治疗慢性感染的癌症治疗。
-
公开(公告)号：US20070105768A1
公开(公告)日：2007-05-10
申请号：US10578692
申请日：2004-11-10
Applicant: Rajiv Nayar , Mark Manning , Philip Barr , Philip Pemberton , Ian Bathurst , Helen Gibson
Inventor： Rajiv Nayar , Mark Manning , Philip Barr , Philip Pemberton , Ian Bathurst , Helen Gibson
IPC: A61K38/36
CPC classification number: A61K38/57 , A61K9/19 , A61K47/02 , A61K47/26 , C07K14/8125
Abstract: A dry powder composition comprises recombinant human alpha 1-antitrypsin (rAAAT).
Abstract translation: 干粉组合物包含重组人α1-抗胰蛋白酶（rAAAT）。
-
公开(公告)号：US06689353B1
公开(公告)日：2004-02-10
申请号：US09605577
申请日：2000-06-28
Applicant: Wei Wang , Rajiv Nayar , Michael A. Shearer
Inventor： Wei Wang , Rajiv Nayar , Michael A. Shearer
IPC: A61K3820
CPC classification number: A61K38/2013
Abstract: A stable pharmaceutical preparation comprising Human interleukin-2 or a variant thereof and a stabilizing amount of histidine. A preferred formulation includes glycine and sucrose and a variant of IL-2 having a single mutation, N88R. The preferred formulation is in lyophilized form which, on reconstitution with an aqueous diluent, results in a solution having a pH ranging from about 5.0 to 6.5.
Abstract translation: 一种稳定的药物制剂，其包含人白细胞介素-2或其变体和稳定量的组氨酸。 优选的制剂包括甘氨酸和蔗糖以及具有单一突变的N88R的IL-2的变体。 优选的制剂是冻干形式，其在与水性稀释剂重建时产生pH范围为约5.0至6.5的溶液。
-
6.发明授权Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations 失效用于鼻内给药的组合物，其制备方法以及从药物制剂中除去残留溶剂的方法
公开(公告)号：US06391452B1
公开(公告)日：2002-05-21
申请号：US09118463
申请日：1998-07-17
Applicant: Kris P. Antonsen , Rajiv Nayar , Wei Wang , Margaret Caudle , Michael A. Shearer , Neville M. Concessio
Inventor： Kris P. Antonsen , Rajiv Nayar , Wei Wang , Margaret Caudle , Michael A. Shearer , Neville M. Concessio
IPC: B32B1502
CPC classification number: C07K14/70525 , A61K9/0043 , A61K9/1658 , A61K38/00 , Y10T428/2984
Abstract: The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e.g., antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.
Abstract translation: 本发明涉及用于递送旨在存在于鼻中的药物的药物组合物，用于鼻内给药的组合物，例如抗病毒剂，特别是包含人类主要鼻病毒受体（也称为细胞间粘附分子-1）的抗病毒剂 ICAM-1）; 制备所述鼻用药物组合物的方法，以及用于从药物基质中除去残余溶剂的改进方法。
-
7.发明申请HIGH THROUGHPUT APPROACH TO FORMULATION USING PRE-DESIGNED FORMULATION PLATES 审中-公开使用预先设计的制剂板制备高通量方法
公开(公告)号：US20120122707A1
公开(公告)日：2012-05-17
申请号：US13299355
申请日：2011-11-17
Applicant: Rajiv Nayar , Mitra Mosharraf
Inventor： Rajiv Nayar , Mitra Mosharraf
CPC classification number: G01N33/68
Abstract: System and methods provide formulation using pre-designed formulation plates for rapidly formulating proteins and peptides, wherein proteins are added to a plurality of wells in the plate; means for stressing one or more protein formulations; and means for analyzing samples of the protein formulations.
Abstract translation: 系统和方法提供使用预先设计的制剂板的制剂，用于快速配制蛋白质和肽，其中将蛋白质加入到板中的多个孔中; 用于强调一种或多种蛋白质制剂的方法; 以及用于分析蛋白质制剂样品的方法。
-
公开(公告)号：US20050152979A1
公开(公告)日：2005-07-14
申请号：US10925797
申请日：2004-08-25
Applicant: Marc Besman , John Carpenter , Mark Manning , Lotte McNamara , Rajiv Nayar
Inventor： Marc Besman , John Carpenter , Mark Manning , Lotte McNamara , Rajiv Nayar
IPC: A61K20060101 , A61K31/335 , A61K31/337 , A61K31/427 , A61K31/4745 , A61K31/7012 , A61K31/7048 , A61K38/16
CPC classification number: A61K31/335 , A61K9/0019 , A61K9/19 , A61K47/26
Abstract: Disclosed are compositions comprising a hydrophobic active agent, a polymer and a reconstitution enhancing agent. Reconstitution of the lyophilized form of the compositions takes less time than in the absence of the enhancing agent.
Abstract translation: 公开了包含疏水性活性剂，聚合物和重构增强剂的组合物。 组合物的冻干形式的重组比不存在增强剂时更少的时间。
-
公开(公告)号：US4983397A
公开(公告)日：1991-01-08
申请号：US888601
申请日：1986-07-21
Applicant: Alan J. Schroit , Rajiv Nayar
Inventor： Alan J. Schroit , Rajiv Nayar
IPC: A61K9/127
CPC classification number: A61K9/1271 , Y10S436/829 , Y10S514/974 , Y10T428/2984
Abstract: Liposome dispersions are prepared from (a) a synthetic phospholipid of the cephaline type in which the amino group is monoacylated with a dicarboxylic acid; (b) a synthetic phospholipid of the cephaline type; and (c) one or more compounds having pharmacological activity. The mixture optionally can contain phospholipids of natural sources and a pharmaceutical carrier solution buffered to pH 7.0 to 7.8.
Abstract translation: 脂质体分散体由（a）头孢氨酸类型的合成磷脂制备，其中氨基用二羧酸单酰化; （b）头孢类的合成磷脂; 和（c）一种或多种具有药理活性的化合物。 混合物任选地可以含有天然来源的磷脂和缓冲至pH 7.0至7.8的药物载体溶液。
-
10.发明申请
公开(公告)号：US20140271815A1
公开(公告)日：2014-09-18
申请号：US13837637
申请日：2013-03-15
Applicant: Aryo Sorayya , Rajiv Nayar , Mitra Mosharraf
Inventor： Aryo Sorayya , Rajiv Nayar , Mitra Mosharraf
CPC classification number: A61K47/24 , A61K9/1272 , A61K9/19 , A61K39/39 , A61K2039/55555
Abstract: A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: Dipalmitoyl phosphatidlcholine (DPPC), Dipalmitoyl phosphatidylglycerol (DPPG), Dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.
Abstract translation: 一种疫苗佐剂组合物，其包含：选自以下的脂质：二棕榈酰磷脂酰胆碱（DPPC），二棕榈酰磷脂酰甘油（DPPG），二油酰磷脂酰胆碱（DOPC）和胆固醇，并含有带有相关/夹带蛋白抗原的带正电荷或带负电荷的脂质。
